Work

Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-166986

Authors: Deepti H. Radia, Jason Gotlib, Mark W. Drummond, Tracy I. George, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Daniel J. DeAngelo, Andreas Reiter

Institutions: Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, Stanford Medicine, Stanford Cancer Institute, Stanford University, Beatson West of Scotland Cancer Centre, ARUP Laboratories (United States), Blueprint Medicines (United States), Versiti Blood Center of Wisconsin, Dana-Farber Cancer Institute, University Medical Centre Mannheim

Language: English

Topic: Mast cells and histamine

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310160992

FWCI: 0.153

Cites:

Cited by: 2

Related to: 10